Skip to main content
. 2020 Oct 29;12(11):3173. doi: 10.3390/cancers12113173

Figure 4.

Figure 4

Tumor PD-L1 engagement by 3 distinct PD-L1 therapeutic antibodies quantified using [64Cu] WL12. (A–E) [64Cu]WL12 uptake in MDA-MB-231 xenografts is significantly reduced in mice receiving AtzMab (20 mg/kg), AveMab (10 mg/kg), or DurMab (10 mg/kg) 24 h prior to radiotracer injection. Whole-body volume-rendered [64Cu]WL12 PET-CT images of saline- (A) AtzMab- (B) AveMab- (C) and DurMab-treated (D) mice, and ex vivo biodistribution (E) at 2 h after [64Cu]WL12 injection (n = 6–9/group). (F) IHC staining for PD-L1 in the corresponding tumor. Scale bars: 100 μm. Box-and-whisker graphs showing minimum to maximum and all data points, with the horizontal line representing the median. **** p < 0.0001; NS, not significant, by 1-way ANOVA and Dunnett’s multiple comparisons test in E (From [173]).